A New Frontier in Immuno-Oncology

actym therapeutics word
Logo for LinkedIn 75.png

Targeting intractable immune pathways in the tumor microenvironment

Management Team

President, CEO, and Cofounder
Chief Development Officer
Vice President of Research and Cofounder
Executive Director, Translational and Clinical Sciences
Chief Medical Advisor
Head of Operations

Scientific Advisory Board

Greg Barton, Ph.D.
Paul Rennert, Ph.D. 
Samuel Miller, M.D.
Denise Monack, Ph.D.
Mario Sznol, M.D.

Clinical Advisory Board

Jean Pierre Bizzari, M.D.
Joel Randolph Hecht, M.D.
Jason Luke, M.D.
Mario Sznol, M.D.


BERKELEY, Calif., Nov. 12, 2021 

BERKELEY, Calif., Nov. 11, 2021 

BERKELEY, Calif., May 26, 2021

Dr. Laura Hix Glickman, Cofounder and Vice President of Research, has been invited to speak at the STING & TLR-Targeting Therapies Digital Summit on May 26, 2021

BERKELEY, Calif., January 13, 2021   

Newly Appointed Members Include Dr. Lawrence Fong, M.D. and Dr. Michel Streuli, Ph.D.

BERKELEY, Calif., April 27, 2020   

Financing will fund Actym’s cancer immunotherapy pipeline into clinical development

BERKELEY, Calif., Nov 7, 2019  PRNewswire

The presentation will highlight Actym’s novel tumor-specific therapies that deliver multiplexed immunomodulatory payloads after systemic administration.

BERKELEY, Calif., April 10, 2019

Actym Therapeutics announced that Dr. Christopher Thanos, President, CEO, and Cofounder, has been invited to speak at the 15th annual PEGS Conference in Boston, MA.

Apr 02, 2019 PRNewswire

Two presentations will highlight Actym's novel IV administered, tumor-infiltrating therapies that express immuno-modulatory factors

Nov 8, 2018 PRNewswire

Presentation will focus on a novel tumor-targeting, systemically-delivered STING pathway agonist that demonstrates robust anti-tumor efficacy in multiple murine cancer models.

actym therapeutics logo

Contact Us

Actym Therapeutics

626 Bancroft Way

Suite A

Berkeley, CA 94710

actym therapeutics vector